Drug Profile
IMM 01
Alternative Names: IMM-01Latest Information Update: 24 Sep 2020
Price :
$50
*
At a glance
- Originator Immunova
- Developer Modulate Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Sep 2020 Preclinical development is ongoing Canada
- 24 Sep 2020 Modulate Therapeutics plans a phase I trial for Cancer in June 2021
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in Canada (Intratumoural)